$TORO

The Toro Company Q3 2026 Earnings Call Summary

The Toro Company reported Q3 2026 net sales growth of 8%, driven by landscape contractor and underground construction products. Residential margins expanded by 400 basis points. Full-year adjusted EPS guidance was raised to $4.60–$4.65. The company recorded a $43 million non-cash impairment charge and adjusted IEEPA refund expectations. Management highlighted growth opportunities in underground construction and data centers, and plans for a successor to the AMP productivity initiative.

Original reporting
Published Sep 5, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Toro Company Q3 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$TOROBullishHigh
01

Why it matters

The raised guidance and strong cash conversion suggest improved earnings momentum.

02

Market read

Earnings beat and guidance raise are likely to drive short‑term price movement.

03

What to watch

Potential tariff exposure from Canada and weather‑related demand volatility.

Relevance 8/10Novelty 8/10Timing: post‑earnings release

Background

Toro's Q3 2026 earnings call highlighted sales growth, margin expansion, and a new EPS outlook.

Company-level read

Ticker impact

$TOROBullishHigh confidence
Context

Toro raised full-year adjusted EPS guidance to $4.60‑$4.65 and reported 8% sales growth, indicating stronger earnings outlook.

Expected impact

Potential upside of 5‑10% on the next trading day.

Evidence & confidence

Guidance lift is material, first disclosed, and aligns with strong cash flow and margin expansion.

Market effects

Positive signal for the landscaping and construction equipment sector.

U.S. industrial equipment market may see modest gains.

Limited to North American equipment manufacturers.

Counterpoint

If the guidance raise is already priced in, the stock could face a short‑term pullback.

Key entities

  • The Toro Company

    U.S. listed manufacturer of landscaping and construction equipment.

Related articles

$TOROHighAI 8/10

Why is Toro stock surging today?

Toro Corp (TORO) stock rose 7.2% to $6.88 in pre-market trading after announcing plans to spin off its LPG carrier business into a new Nasdaq-listed company, AI Okto Corp, with $45M in cash. Existing shareholders will receive AI Okto shares for free, driving the surge despite a broader market decline.

$COOMed

After-Hours Movers: COO, AEO, NAVN, AVAV, TORO

Cooper Cos. (COO) dropped 18% after retaining CooperSurgical and lowering Q4 and full-year guidance. American Eagle (AEO) fell 12% despite a Q2 beat due to profit-taking. Navan (NAVN) declined 11% after a beat-and-raise. AeroVironment (AVAV) rose 3% on a strong Q1 beat. Toro (TORO) gained 4% on plans to spin off its LPG fleet.

$005930.KSMedAI 8/10

Samsung, SK hynix Set to Post Record Q3 Operating Profit

Samsung Electronics and SK hynix are expected to post record Q3 operating profits, driven by high memory demand and supply shortages. Samsung's profit is estimated at 111.38 trillion won, up 815.47% YoY, while SK hynix's profit is forecast at 78.13 trillion won, up 586.34% YoY. Both companies are focusing on HBM for AI semiconductors, exacerbating general-purpose DRAM shortages.

$SNXMed

TD Synnex: Morgan Stanley lifts price target after strong quarter

Morgan Stanley raised its price target for TD Synnex Corp (NYSE:SNX) to $359 from $334, citing stronger-than-expected earnings, accelerating growth, and improving operating leverage. The company's fiscal third-quarter revenue and EPS beat estimates by 13%-21%, with fourth-quarter guidance 12%-25% above expectations. Analysts also increased fiscal 2027 and 2028 earnings estimates by 12%-15%, driven by enterprise AI demand and new hyperscaler programs.

$LLYMed

Lilly’s Oral GLP-1 Push Gains Momentum. Can Foundayo Become its Next Growth Engine?

Eli Lilly (LLY) reports that Foundayo, its oral GLP-1 drug, now accounts for about one-third of new patients starting the treatment. Foundayo generated $98 million in Q2 revenue, contributing to Lilly's total Q2 revenue of $23.0 billion, up 48% YoY. Lilly raised its 2026 revenue guidance to $85 billion-$87 billion and is investing $6.5 billion in a new Houston facility to produce Foundayo and other medicines.